Liver Decompensation Risk after Hepatectomy for Hepatocellular Carcinoma (HCC)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–5
- Intermediate Risk20–35
- High Risk55–65
The Liver Decompensation Risk after Hepatectomy for Hepatocellular Carcinoma (HCC) calculates predicting risk of liver decompensation after hepatectomy for hepatocellular carcinoma (HCC). Key inputs include portal hypertension. Scores guide timing emergent endoscopy, initiating high-dose proton pump inhibitor infusions, or obtaining surgical consultation. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Predicts risk of liver decompensation after hepatectomy for hepatocellular carcinoma (HCC)
Clinical Indication
The Liver Decompensation Risk after Hepatectomy for Hepatocellular Carcinoma (HCC) is indicated for bedside clinical practice to support Predicts risk of liver decompensation after hepatectomy for hepatocellular carcinoma (HCC). It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with upper or lower gastrointestinal hemorrhage, acute pancreatitis, acute liver failure, or inflammatory bowel disease. Clinical application is indicated across Endoscopy suites, emergency GI triage, acute medical floors, and hepatology services.
Limitations & Contraindications
Initial hemoglobin values in hyperacute hemorrhage may falsely appear normal prior to complete extravascular-to-intravascular fluid equilibration.
Clinical Pearls & Action Plan
Aggressive intravascular volume resuscitation and blood product support must precede diagnostic or therapeutic endoscopy. Guideline pearl: Higher risk patients may benefit from alternative treatments or enhanced perioperative monitoring.
Risk stratification based on hierarchical interaction of portal hypertension, hepatectomy extent, and MELD score. Low risk: no portal hypertension + minor resection + MELD ≤9. Intermediate risk: no portal hypertension + major resection OR minor resection + (portal hypertension OR MELD >9). High risk: major resection + portal hypertension.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| portal_hypertension | string | Yes | Portal hypertension defined as F1 esophageal varices on endoscopy OR platelets <100,000/μL with splenomegaly |
| hepatectomy_extent | string | Yes | Extension of hepatectomy - Major resection = removal of ≥3 adjacent segments |
| meld_score_category | string | No | MELD score category (only required if no portal hypertension and minor hepatectomy) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–5 | Low Risk | Low risk of liver decompensation |
| 20–35 | Intermediate Risk | Intermediate risk of liver decompensation |
| 55–65 | High Risk | High risk of liver decompensation |
Evidence-Based References (EBM)
- Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, Berretta M, et al. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg. 2012 Nov;256(5):706-12; discussion 712-3. doi: 10.1097/SLA.0b013e3182724258.DOI: 10.1097/SLA.0b013e3182724258
- Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, La Barba G, et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl. 2006 Jun;12(6):966-71. doi: 10.1002/lt.20769.DOI: 10.1002/lt.20769
- Santambrogio R, Kluger MD, Costa M, Belli A, Barabino M, Laurent A, et al. Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh's A cirrhosis: is clinical evidence of portal hypertension a contraindication? HPB (Oxford). 2013 Jan;15(1):78-84. doi: 10.1111/j.1477-2574.2012.00583.x.DOI: 10.1111/j.1477-2574.2012.00583.x